Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
Sponsor

Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

Austria Muellner Hauptstrasse 48, 5020 Salzburg, Austria

About the sponsor

The sponsor is involved in clinical research for locally advanced and metastatic squamous cell carcinoma of the skin, with interest in immune checkpoint therapy and treatment strategies for advanced cutaneous malignancies.

  • Nivolumab
  • Relatlimab
  • RECIST 1.1

These activities reflect a focus on solid tumor management in skin cancer, including disease control and response assessment in advanced dermatologic oncology.

About Specializations

Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH runs clinical trials in conditions such as Squamous cell carcinoma of skin, Adenocarcinoma pancreas, Erysipelas, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

3 clinical trials

Squamous cell carcinoma of skin

Recruiting

Study of Nivolumab and Nivolumab Plus Relatlimab for Patients with Advanced or Metastatic Skin Squamous Cell Carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

Adenocarcinoma pancreas

Not yet recruiting

Diagnostic Performance of [68Ga]Ga-HKG301 PET/CT with FAP-2286 in Patients with Pancreatic Adenocarcinoma and Invasive Lobular Breast Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:FAP-2286
  • Sponsor:Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

Erysipelas

Not yet recruiting

A study to evaluate the safety and effectiveness of dalbavancin in patients with erysipelas or limited cellulitis being treated at home.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dalbavancin
  • Sponsor:Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.